After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s point-of-care Car-T push looks to have stalled.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
